Fulcrum Therapeutics (FULC) Income towards Parent Company (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Income towards Parent Company of -$35.0 million for Q2 2026, down 102.27% year-over-year from $1.5 billion in Q2 2025, and up 29.98% quarter-over-quarter from -$50.0 million in Q1 2026.
Fulcrum Therapeutics (FULC) Income towards Parent Company (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Income towards Parent Company for 9 consecutive years, with -$35.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Income towards Parent Company fell 102.27% year-over-year to -$35.0 million; the TTM figure through Jun 2026 stood at -$188.7 million (down 101.92% YoY), while the FY2025 annual figure was -$161.2 million, down 119.71% from the prior year.
- Income towards Parent Company grew to -$35.0 million in Q2 2026 per FULC's latest filing, from -$50.0 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $55.4 million in Q2 2024 and bottomed at -$94.0 million in Q1 2022.
- Historically, Income towards Parent Company has averaged -$35.5 million across 5 years, with a median of -$32.4 million in 2022.
- Annual changes were most pronounced in 2024 — Income towards Parent Company soared 332.98% — and 2025, when it slumped 236.18%.
- Fulcrum Therapeutics' Income towards Parent Company stood at -$29.9 million in 2022, then slumped by 44.37% to -$43.1 million in 2023, then soared by 41.93% to -$25.0 million in 2024, then plunged by 236.18% to -$84.2 million in 2025, then soared by 58.43% to -$35.0 million in 2026.
- Business Quant data shows FULC's Income towards Parent Company at -$35.0 million in Q2 2026, -$50.0 million in Q1 2026, and -$84.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.98 Mn |
| Mar 31, 2026 | -49.97 Mn |
| Dec 31, 2025 | -84.15 Mn |
| Sep 30, 2025 | -19.60 Mn |
| Jun 30, 2025 | -17.30 Mn |
| Mar 31, 2025 | -29.43 Mn |
| Dec 31, 2024 | -25.03 Mn |
| Sep 30, 2024 | -21.70 Mn |
| Jun 30, 2024 | 55.41 Mn |
| Mar 31, 2024 | -65.24 Mn |
| Dec 31, 2023 | -43.11 Mn |
| Sep 30, 2023 | -24.02 Mn |
| Jun 30, 2023 | -23.78 Mn |
| Mar 31, 2023 | -30.52 Mn |
| Dec 31, 2022 | -192.46 Mn |
| Sep 30, 2022 | -27.08 Mn |
| Jun 30, 2022 | -35.44 Mn |
| Mar 31, 2022 | -94.00 Mn |
| Dec 31, 2021 | -50.95 Mn |
| Sep 30, 2021 | -96.47 Mn |